Teva Pharmaceutical Tanks as Stock Cycles Highlight Downside Risk

Teva Pharmaceutical (TEVA) fell 9% on Wednesday morning, after it posted earnings that missed Wall Street expectations.

The stock’s market cycles point to a period of increasing risk as the current cycle matures, resuming a declining phase…

Teva reported earnings per share of $0.53 and total revenue of $4.56 billion, compared to analyst estimates of $0.55 and $4.52 billion. With regards to guidance, its forecasted earnings and revenue that were below the average analyst estimates.

CEO Kare Schultz explained that, “Looking ahead, we continue to expect that 2019 will be the trough for our business,” noting that growth would return in 2020.

Sign up for our FREE newsletter
and receive our best trading ideas and research

With regard to Teva’s market cycles, we can see that the stock has already broken below the point at which it began the cycle. It attempted to rally back up to that point but failed.

We expect downside risk to increase as the current cycle matures, with a target below $15 by early-April.

Teva Pharmaceutical (TEVA) Stock Weekly Chart

teva pharmaceutical stock research analysis february 13

For more from Slim, or to learn about cycle analysis, check out the askSlim Market Week show every Friday on our YouTube channel.

Twitter:  @askslim

Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.